TickerFacts.

Coya Therapeutics, Inc. (COYA): Revenue

Annual figures by period end, from SEC filings.

$7.95M
Year ended 2025-12-31
$8.02M
Trailing 12 months to 2026-06-30
2022-12-31: $02023-12-31: $6.00M2024-12-31: $3.55M2025-12-31: $7.95M$7.95M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$7.95M+123.6%2026-03-16, From 2025-01-01
2024-12-31$3.55M-40.8%2026-03-16, From 2024-01-01
2023-12-31$6.00Mn/a2025-03-18, From 2023-01-01
2022-12-31$0n/a2024-03-19, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Coya Therapeutics, Inc. (COYA)2025-12-31$7.95M+123.6%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$7.83M-58.2%
Bolt Biotherapeutics, Inc. (BOLT)2025-12-31$7.70M+0.1%
Adagene Inc. (ADAG)2025-12-31$7.67Mn/m
Roivant Sciences Ltd. (ROIV)2026-03-31$8.26M-71.6%
Xenon Pharmaceuticals Inc. (XENE)2025-12-31$7.50Mn/a
Ovid Therapeutics Inc. (OVID)2025-12-31$7.25Mn/m
Whitehawk Therapeutics, Inc. (WHWK)2025-12-31$7.14M-72.5%
BioAge Labs, Inc. (BIOA)2025-12-31$8.99Mn/a

Compare COYA, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗